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file, hypothyroid-specific health-related quality-of-
life scores, and 13 neuropsychological measures
pre- and posttreatment. This study detected no dif-
ference in body weight and serum lipids at baseline
and after treatment. The hypothyroid-specific
health-related quality-of-life scores similarly
improved for both treatment groups. Twelve of 13
neuropsychological tests demonstrated no differ-
ences between treatment groups; the Grooved Peg
Board Test of manual dexterity and fine visual-
motor coordination demonstrated a slight improve-
ment for the LT4 alone treatment group.4
The initial dose of LT4 can be based on the age
and health status of the patient. The mean replace-
ment dose of LT4 is 1.6 µg/kg/d for healthy patients
aged ≤60 years.5–7 Patients aged >60 years should
be started on 25 to 50 µg daily. An uncontrolled
cohort study of 84 patients found that for patients
aged >60 years, 25- to 50-µg doses of LT4 resulted
in similar serum thyrotropin (TSH) levels as the
higher (1.6 µg/kg/d) doses required for younger
patients.7 Based on expert opinion, patients of any
age with heart disease should be given lower doses
of 12.5 to 25 µg daily as initial treatment.1,2
The choice of the LT4 preparation continues to
be debated. In 1997, a bioequivalence study com-
pared 2 generic brands to 2 name brands by having
22 women with hypothyroidism, who were euthy-
roid on replacement medication, take each prepa-
ration for 6 weeks.8 The area under the curve, peak
serum concentration, and time to peak concentra-
tion for 3 indexes of thyroid function (thyroxine,
triiodothyronine, and free T4 index) were not sig-
nificantly different and met the FDA criterion for
relative bioequivalence. However, they did not
examine therapeutic equivalence and from a clini-
cal perspective, some researchers and pharmaceu-
tical companies felt that the authors could not
comment on whether the products were inter-
changeable.8,9 The FDA now requires thyroxine
bioavailability and bioequivalence studies to evalu-
ate product substitution.10 The FDA lists
Levothyroxine Sodium (Mylan) to be therapeuti-
cally equivalent and therefore interchangeable
with Unithroid.11
How should thyroid
replacement be initiated?
■ EVIDENCE-BASED ANSWER 
Levothyroxine (LT4) should be used alone as ini-
tial replacement for patients with hypothyroidism
(strength of recommendation [SOR]: A). The opti-
mal initial dose is 1.6 µg/kg/d for healthy people
aged 60 years or younger (SOR: B). Patients aged
more than 60 years may require less levothyroxine
to achieve therapeutic serum thyroid hormone
replacement, so initial replacement should be
decreased to 25 to 50 µg daily (SOR: C). 
Since patients with known heart disease may
develop dysrhythmias, angina, and myocardial
infarctions when started on full replacement
doses, experts recommend starting 12.5 to 25 µg
daily for this population (SOR: C). Brand-name
(Synthroid, Levoxyl, etc) and generic LT4 are
bioequivalent (SOR: B), although the US Food
and Drug Administration (FDA) does not consid-
er these products to be interchangeable until
proven therapeutically equivalent. 
■ EVIDENCE SUMMARY
Initial thyroid replacement with synthetic LT4 is
recommended because LT4 is safe, effective, reli-
ably relieves symptoms, and normalizes lab tests
for hypothyroid patients.1,2
Two recent randomized trials comparing LT4
alone or LT4 and LT3 together for a total of 86
adult hypothyroid patients found similar outcomes.
One study, which enrolled patients with hypothy-
roidism and mild depressive symptoms, assessed
scores on the Symptom Check-List-90, the
Comprehensive Epidemiological Screens for
Depression, and the Medical Outcomes Study
health status questionnaire at baseline and multi-
ple times over the duration of the study. For these
outcomes, no differences were found between the
LT4 alone and combination LT4-LT3 treatment
groups within 90% confidence intervals.3 A second
study assessed changes in body weight, lipid pro-
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■ RECOMMENDATIONS FROM OTHERS
The American Association of Clinical
Endocrinologists Thyroid Task Force recommends
the use of a high-quality brand preparation of LT4
rather than desiccated thyroid hormone, combina-
tions of thyroid hormones, or LT3.12 It recommends
a mean replacement dosage of LT4 of 1.6 µg/kg of
body weight per day with initial dose ranging from
12.5 µg daily to a full replacement dosage based on
the age, weight, and cardiac status of the patient.
UpToDate states that although LT4 products
are standardized, subtle differences between
preparations exist, and products should be inter-
changed only with sufficient monitoring after the
change. In addition, they recommend generally
avoiding generics because the pharmacy may inter-
change products without physicians being aware.1
The Physicians’ Information and Education
Resource from the American College of Physicians
states “Name-brand LT4 products provide more
consistent potency than generic preparations. The
cost of brand-name LT4 products is only slightly
more than that of generic preparations.”2
Suzanne E. Landis, MD, MPH, University of North
Carolina at Chapel Hill, Mountain Area Health Education
Center, Asheville, NC; Linda J. Collins, MSLS, University
of North Carolina at Chapel Hill
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■ CLINICAL COMMENTARY
Instruct patients about the timing of
levothyroxine and potential interactions
The starting dose of levothyroxine for
hypothyroid patients is based on age, severi-
ty of the disease, duration of the disease, and
existing comorbid conditions. For healthy
adults 60 years of age or younger, the optimal
starting dose is 1.6 µg/kg/d. For patients
more than 60 years of age, the initial dose is
25 to 50 µg/d. To avoid cardiac complications
among persons with known heart disease,
the recommended initial levothyroxine dose
is 12.5 µg/d. In my experience, these guide-
lines work well in initiating treatment for
hypothyroidism. 
Few of my patients have noted any difference
between generic and brand-name thyroid sup-
plements. Knowing what other medications
the patient is taking is important, since med-
ications such as estrogen can decrease the
bioavailability of levothyroxine by increasing
binding proteins. It is also important to
instruct patients about the timing of levothy-
roxine intake, because some medications can
affect absorption (eg, cholestyramine, calcium,
or iron).
Santhi Penmetsa, MD, Department of Family and
Community Medicine, Baylor College of Medicine
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